Hurdles in therapy with regulatory T cells

Piotr Trzonkowski; Rosa Bacchetta; Manuela Battaglia; David Berglund; Hermann Richard Bohnenkamp; Anja ten Brinke; Andrew Bushell; Nathalie Cools; Edward K Geissler; Silvia Gregori; S Marieke van Ham; Catharien Hilkens; James A Hutchinson; Giovanna Lombardi; J Alejandro Madrigal; Natalia Marek-Trzonkowska; Eva M Martinez-Caceres; Maria Grazia Roncarolo; Silvia Sanchez-Ramon; Aurore Saudemont; Birgit Sawitzki

doi:10.1126/scitranslmed.aaa7721

Hurdles in therapy with regulatory T cells

Piotr Trzonkowski, Rosa Bacchetta, Manuela Battaglia, David Berglund, Hermann Richard Bohnenkamp, Anja ten Brinke, Andrew Bushell, Nathalie Cools, Edward K Geissler, Silvia Gregori, S Marieke van Ham, Catharien Hilkens, James A Hutchinson, Giovanna Lombardi, J Alejandro Madrigal, Natalia Marek-Trzonkowska, Eva M Martinez-Caceres, Maria Grazia Roncarolo, Silvia Sanchez-Ramon, Aurore SaudemontBirgit Sawitzki

Research output: Contribution to journal › Article › peer-review

133 Citations (Scopus)

Abstract

Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT," which identifies hurdles hindering Treg clinical applications in Europe and provides possible solutions.

Original language	English
Pages (from-to)	304ps18
Journal	Science Translational Medicine
Volume	7
Issue number	304
DOIs	https://doi.org/10.1126/scitranslmed.aaa7721
Publication status	Published - 9 Sept 2015

Keywords

Clinical Trials as Topic
Drug Approval
Humans
Immunotherapy
T-Lymphocytes, Regulatory
Treatment Outcome

Access to Document

10.1126/scitranslmed.aaa7721

Cite this

Trzonkowski, P., Bacchetta, R., Battaglia, M., Berglund, D., Bohnenkamp, H. R., ten Brinke, A., Bushell, A., Cools, N., Geissler, E. K., Gregori, S., Marieke van Ham, S., Hilkens, C., Hutchinson, J. A., Lombardi, G., Madrigal, J. A., Marek-Trzonkowska, N., Martinez-Caceres, E. M., Roncarolo, M. G., Sanchez-Ramon, S., ... Sawitzki, B. (2015). Hurdles in therapy with regulatory T cells. Science Translational Medicine, 7(304), 304ps18. https://doi.org/10.1126/scitranslmed.aaa7721

@article{ecd0aa6c80d34c51a9dfcf9431c628b9,

title = "Hurdles in therapy with regulatory T cells",

abstract = "Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, {"}Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT,{"} which identifies hurdles hindering Treg clinical applications in Europe and provides possible solutions.",

keywords = "Clinical Trials as Topic, Drug Approval, Humans, Immunotherapy, T-Lymphocytes, Regulatory, Treatment Outcome",

author = "Piotr Trzonkowski and Rosa Bacchetta and Manuela Battaglia and David Berglund and Bohnenkamp, {Hermann Richard} and {ten Brinke}, Anja and Andrew Bushell and Nathalie Cools and Geissler, {Edward K} and Silvia Gregori and {Marieke van Ham}, S and Catharien Hilkens and Hutchinson, {James A} and Giovanna Lombardi and Madrigal, {J Alejandro} and Natalia Marek-Trzonkowska and Martinez-Caceres, {Eva M} and Roncarolo, {Maria Grazia} and Silvia Sanchez-Ramon and Aurore Saudemont and Birgit Sawitzki",

note = "Copyright {\textcopyright} 2015, American Association for the Advancement of Science.",

year = "2015",

month = sep,

day = "9",

doi = "10.1126/scitranslmed.aaa7721",

language = "English",

volume = "7",

pages = "304ps18",

journal = "Science Translational Medicine",

issn = "1946-6234",

publisher = "American Association for the Advancement of Science",

number = "304",

}

Trzonkowski, P, Bacchetta, R, Battaglia, M, Berglund, D, Bohnenkamp, HR, ten Brinke, A, Bushell, A, Cools, N, Geissler, EK, Gregori, S, Marieke van Ham, S, Hilkens, C, Hutchinson, JA, Lombardi, G, Madrigal, JA, Marek-Trzonkowska, N, Martinez-Caceres, EM, Roncarolo, MG, Sanchez-Ramon, S, Saudemont, A & Sawitzki, B 2015, 'Hurdles in therapy with regulatory T cells', Science Translational Medicine, vol. 7, no. 304, pp. 304ps18. https://doi.org/10.1126/scitranslmed.aaa7721

TY - JOUR

T1 - Hurdles in therapy with regulatory T cells

AU - Trzonkowski, Piotr

AU - Bacchetta, Rosa

AU - Battaglia, Manuela

AU - Berglund, David

AU - Bohnenkamp, Hermann Richard

AU - ten Brinke, Anja

AU - Bushell, Andrew

AU - Cools, Nathalie

AU - Geissler, Edward K

AU - Gregori, Silvia

AU - Marieke van Ham, S

AU - Hilkens, Catharien

AU - Hutchinson, James A

AU - Lombardi, Giovanna

AU - Madrigal, J Alejandro

AU - Marek-Trzonkowska, Natalia

AU - Martinez-Caceres, Eva M

AU - Roncarolo, Maria Grazia

AU - Sanchez-Ramon, Silvia

AU - Saudemont, Aurore

AU - Sawitzki, Birgit

PY - 2015/9/9

Y1 - 2015/9/9

N2 - Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT," which identifies hurdles hindering Treg clinical applications in Europe and provides possible solutions.

AB - Improper activation of the immune system contributes to a variety of clinical conditions, including autoimmune and allergic diseases as well as solid organ and bone marrow transplantation. One approach to counteract this activation is through adoptive therapy with regulatory T cells (Tregs). Efforts to manufacture these cells have led to good maunfacturing practice-compliant protocols, and Treg products are entering early clinical trials. Here, we report the stance of the European Union Cooperation in Science and Technology Action BM1305, "Action to Focus and Accelerate Cell-based Tolerance-inducing Therapies-A FACTT," which identifies hurdles hindering Treg clinical applications in Europe and provides possible solutions.

KW - Clinical Trials as Topic

KW - Drug Approval

KW - Humans

KW - Immunotherapy

KW - T-Lymphocytes, Regulatory

KW - Treatment Outcome

U2 - 10.1126/scitranslmed.aaa7721

DO - 10.1126/scitranslmed.aaa7721

M3 - Article

C2 - 26355029

SN - 1946-6234

VL - 7

SP - 304ps18

JO - Science Translational Medicine

JF - Science Translational Medicine

IS - 304

ER -

Hurdles in therapy with regulatory T cells

Abstract

Keywords

Access to Document

Fingerprint

Cite this